A digital revolution is sweeping through the pharmaceutical industry, and it’s powered by artificial intelligence (AI). From automating drug discovery to making clinical trials more efficient and driving breakthroughs in biotechnology, AI is reshaping the healthcare landscape. And India, long known as the ‘pharmacy of the world, is positioning itself to ride this wave of innovation, as it should! India’s pharmaceutical sector has always been a global heavyweight. As the world’s third-largest producer of drugs by volume, it has historically focused on affordable generics. But now, with the infusion of AI-driven capabilities, the industry is shifting gears—becoming a hub of R&D, innovation, and precision medicine.
As per a EY-Pantheon and Microsoft report that tracked the sector, AI market in pharmaceuticals is projected to hit USD16.49 billion by 2034 and AI-driven medical devices are set to grow to USD97.07 billion globally by 2028. India must move quickly and decisively to gain the necessary advantage and leverage.
Major Indian pharmaceutical firms such as Sun Pharma, Dr Reddy’s Laboratories, and Cipla are investing heavily in AI technologies. Their goal: reduce the spiralling costs and timeframes associated with developing new drugs, and leapfrog into the realm of novel therapeutics. Meanwhile, India’s homegrown AI startups are gaining momentum by offering specialised solutions across the pharma value chain. Companies like Qure.ai, Indegene, and AIRA Matrix are helping digitise diagnostics, streamline clinical trial processes, and ensure regulatory compliance through advanced analytics and automation.
Qure.ai, for example, has developed deep learning algorithms capable of interpreting complex medical images like X-rays and CT scans. These tools are not only helping doctors make faster and more accurate diagnoses but are also being integrated into clinical trial pipelines to identify suitable patient cohorts. Indegene, on the other hand, supports pharma companies in managing large datasets and enhancing patient engagement using AI-powered systems—bringing a new level of precision to the business side of medicine.
Source: millenniumpost
#healthcarestartup #india #dseidehealthcarenetwork
As per a EY-Pantheon and Microsoft report that tracked the sector, AI market in pharmaceuticals is projected to hit USD16.49 billion by 2034 and AI-driven medical devices are set to grow to USD97.07 billion globally by 2028. India must move quickly and decisively to gain the necessary advantage and leverage.
Major Indian pharmaceutical firms such as Sun Pharma, Dr Reddy’s Laboratories, and Cipla are investing heavily in AI technologies. Their goal: reduce the spiralling costs and timeframes associated with developing new drugs, and leapfrog into the realm of novel therapeutics. Meanwhile, India’s homegrown AI startups are gaining momentum by offering specialised solutions across the pharma value chain. Companies like Qure.ai, Indegene, and AIRA Matrix are helping digitise diagnostics, streamline clinical trial processes, and ensure regulatory compliance through advanced analytics and automation.
Qure.ai, for example, has developed deep learning algorithms capable of interpreting complex medical images like X-rays and CT scans. These tools are not only helping doctors make faster and more accurate diagnoses but are also being integrated into clinical trial pipelines to identify suitable patient cohorts. Indegene, on the other hand, supports pharma companies in managing large datasets and enhancing patient engagement using AI-powered systems—bringing a new level of precision to the business side of medicine.
Source: millenniumpost
#healthcarestartup #india #dseidehealthcarenetwork
A digital revolution is sweeping through the pharmaceutical industry, and it’s powered by artificial intelligence (AI). From automating drug discovery to making clinical trials more efficient and driving breakthroughs in biotechnology, AI is reshaping the healthcare landscape. And India, long known as the ‘pharmacy of the world, is positioning itself to ride this wave of innovation, as it should! India’s pharmaceutical sector has always been a global heavyweight. As the world’s third-largest producer of drugs by volume, it has historically focused on affordable generics. But now, with the infusion of AI-driven capabilities, the industry is shifting gears—becoming a hub of R&D, innovation, and precision medicine.
As per a EY-Pantheon and Microsoft report that tracked the sector, AI market in pharmaceuticals is projected to hit USD16.49 billion by 2034 and AI-driven medical devices are set to grow to USD97.07 billion globally by 2028. India must move quickly and decisively to gain the necessary advantage and leverage.
Major Indian pharmaceutical firms such as Sun Pharma, Dr Reddy’s Laboratories, and Cipla are investing heavily in AI technologies. Their goal: reduce the spiralling costs and timeframes associated with developing new drugs, and leapfrog into the realm of novel therapeutics. Meanwhile, India’s homegrown AI startups are gaining momentum by offering specialised solutions across the pharma value chain. Companies like Qure.ai, Indegene, and AIRA Matrix are helping digitise diagnostics, streamline clinical trial processes, and ensure regulatory compliance through advanced analytics and automation.
Qure.ai, for example, has developed deep learning algorithms capable of interpreting complex medical images like X-rays and CT scans. These tools are not only helping doctors make faster and more accurate diagnoses but are also being integrated into clinical trial pipelines to identify suitable patient cohorts. Indegene, on the other hand, supports pharma companies in managing large datasets and enhancing patient engagement using AI-powered systems—bringing a new level of precision to the business side of medicine.
Source: millenniumpost
#healthcarestartup #india #dseidehealthcarenetwork
